Matthias Balk / picture alliance via Getty Images BristolMyersSquibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration. The pharmaceutical firm called ...
Recent results from BristolMyersSquibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-MyersSquibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves BristolMyersSquibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Some results have been hidden because they may be inaccessible to you